Lumos Diagnostics HoldingsASX:LDX 31 PS Ratio is 4.20 as of Jul. 01, 2026, which is 308% above its 10-year median of 1.03. GuruFocus rates ASX:LDX with a GF Score™ of 31/100 and a GF Value™ of A$0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks worse than 64.97% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lumos Diagnostics Holdings's share price is A$0.105.
Lumos Diagnostics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.03. Hence, Lumos Diagnostics Holdings's PS Ratio for today is 4.20.
The historical rank and industry rank for Lumos Diagnostics Holdings's PS Ratio or its related term are showing as below:
ASX:LDX'
s PS Ratio Range Over the Past 10 Years
Min: 0.11 Med: 1.03 Max: 11.43
Current: 4.2
During the past 4 years, Lumos Diagnostics Holdings's highest PS Ratio was 11.43. The lowest was 0.11. And the median was 1.03.
ASX:LDX's PS Ratio is ranked worse than 64.97% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs ASX:LDX: 4.20
During the past 4 years, Lumos Diagnostics Holdings's highest 3-Year average Revenue per Share Growth Rate was -35.00% per year. The lowest was -35.00% per year. And the median was -35.00% per year.
Back to Basics: PS Ratio
Lumos Diagnostics Holdings (ASX:LDX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lumos Diagnostics Holdings PS Ratio Related Terms
Lumos Diagnostics Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lumos Diagnostics Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lumos Diagnostics Holdings's Share Price of today is A$0.105.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lumos Diagnostics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lumos Diagnostics Holdings (ASX:LDX) has a PS Ratio of 4.20 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lumos Diagnostics Holdings and its competitors. This is 308% above median its historical median of 1.03. Over the past decade, Lumos Diagnostics Holdings' PS Ratio has ranged from 0.11 to 11.43. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #523 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 65%.
Is Lumos Diagnostics Holdings' PS Ratio too high?
Lumos Diagnostics Holdings' current PS Ratio of 4.20 is 308% above median its 10-year median of 1.03. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 11.43. The Medical Devices & Instruments industry median PS Ratio is 2.94. Lumos Diagnostics Holdings' value of 4.20 is 42.9% above this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #523 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #523 out of 805 companies for PS Ratio. This places Lumos Diagnostics Holdings in the lower half of its industry. The industry median PS Ratio is 2.94. Lumos Diagnostics Holdings' value of 4.20 is 42.9% above this benchmark. Historically, Lumos Diagnostics Holdings' own PS Ratio has ranged from 0.11 to 11.43 over the past decade. While the company's 10-year median is 1.03 vs. the industry median of 2.94, Lumos Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current PS Ratio of 4.20 is 42.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current PS Ratio is 4.20, which is 308% above median its own 10-year median of 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.11 — trading 425% above its estimated fair value. The current PS Ratio is 4.20, which is 308% above median its 10-year median of 1.03 and 42.9% above the Medical Devices & Instruments industry median of 2.94. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current PS Ratio is 4.20 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of A$0.11 is trading 425% above its estimated GF Value™ of A$0.02.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for ASX:LDX:
PS Ratio: 4.20 (308% above median its 10-year median of 1.03)
GF Value™: A$0.02 vs. price of A$0.11 (425% above fair value)
Industry Position: 42.9% above the Medical Devices & Instruments median (#523 of 805)
No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score
Get the complete analysis for ASX:LDX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
